An Expert’s Experience with a New Feline Anti-NGF Monoclonal Antibody: A Case Study

Nerve growth factor (NGF) has emerged as an important target to control osteoarthritis (OA) pain. One highly effective way to target NGF is through the use of monoclonal antibodies (mAbs), for which there is now an approved and available option for veterinarians. In this webinar, Dr. Tamara Grubb will describe the role of NGF in the pain pathway and share her experience in using the first and only feline anti-NGF mAb therapy. Challenges in identifying and treating chronic pain in cats will also be discussed.

Not looking for CE credit for this course? You can skip entering your information below and proceed to viewing the webinar here.